Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout

INTRODUCTION: The efficacy of pegloticase, a polyethylene glycol (PEG)-conjugated mammalian recombinant uricase, approved for chronic refractory gout, can be limited by the development of antibodies (Ab). Analyses from 2 replicate, 6-month, randomized controlled trials were performed to characterize...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Lipsky, Peter E, Calabrese, Leonard H, Kavanaugh, Arthur, Sundy, John S, Wright, David, Wolfson, Marsha, Becker, Michael A
Format: Artigo
Langue:Inglês
Publié: BioMed Central 2014
Sujets:
Research Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4060440/
https://ncbi.nlm.nih.gov/pubmed/24588936
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/ar4497
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires